211
Views
3
CrossRef citations to date
0
Altmetric
Articles/Brief Reports/Review

The validity of the Danish version of the Fibromyalgia Impact Questionnaire – Revised applied in a clinical setting: a Rasch analysis

ORCID Icon, ORCID Icon, ORCID Icon & ORCID Icon
Pages 385-394 | Accepted 04 Jul 2022, Published online: 04 Aug 2022
 

Abstract

Objective

The aim of this study was to evaluate the psychometric properties of the Danish version of the Fibromyalgia Impact Questionnaire – Revised (FIQR), when used to quantify the severity of disease burden in a Danish population of patients with chronic widespread pain (CWP), including fibromyalgia (FM).

Method

A total of 924 participants diagnosed with CWP and/or FM completed an electronic version of the FIQR via touchscreens in the clinic at referral for specialist care. Data were collected from 1 January 2018 to 3 September 2020. Rasch measurement methods were applied.

Results

Rating scale analysis suggested multiple threshold disordering in the 0–10 category rating scale. A principal component analysis suggested assessment of a multidimensional construct. Thus, the Rasch analysis of the full FIQR was discontinued. Instead, Rasch analyses were performed on the two subscales: ‘function’ and ‘symptoms’. By collapsing the rating scale to a 0–4 category scale, the remaining threshold disordering of both subscale was solved. Only the symptom subscale indicated multidimensionality. There was underfitting misfit of item 21 and overfitting misfit of item 12. No significant differential item functioning, defined by sex, ethnicity, or education, was found.

Conclusion

The FIQR should be considered as an instrument consisting of three separate subscales representing ‘function’, ‘overall impact’, and ‘symptoms’. We recommend calculating and reporting on both a 0–10 and a 0–4 category scale. Also, if using the total FIQR score as an outcome measure, this should be done with caution, until revision of the rating scale.

Acknowledgement

We thank Christian Cato Holm for consultancy regarding the DANFIB.

Disclosure statement

No potential conflict of interest was reported by the authors.

Ethics and consent

The Danish Data Protection Agency has approved DANFIB (Jnr 2012-58-0004). Sensitive personal data were anonymized according to regulations stipulated by the Danish Data Protection Agency. Before enrolment in DANFIB, informed consent was obtained from all patients.

Supplemental data

Supplemental data for this article can be accessed online at https://doi.org/10.1080/03009742.2022.2098631.

Additional information

Funding

This work was supported by the Minister Erna Hamilton Foundation [Jnr 21-2020], the Danish Rheumatism Association [R167-A5693], and the Fond of Bispebjerg and Frederiksberg Hospital. The Parker Institute, Bispebjerg and Frederiksberg Hospital, is supported by a core grant from the Oak Foundation [OCAY-18-774-OFIL].

Log in via your institution

Log in to Taylor & Francis Online

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 65.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 171.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.